Contreversies in the management of PH What is controversial in treatment?
|
|
- Darleen Tyler
- 6 years ago
- Views:
Transcription
1 Contreversies in the management of PH What is controversial in treatment? Service de Pneumologie et Réanimation National reference center for pulmonary hypertension Université Paris Sud Hôpital Antoine Béclère, Clamart, APHP, France Inserm U 999
2 Disclosures Gerald Simonneau -has acted as a consultant and on advisory boards for Actelion Bayer, Eli Lilly, GSK, Novartis, Pfizer -has received lecture fees/honoraria from Actelion Bayer, Eli Lilly, GSK, Novartis, Pfizer -and has received research grants from Actelion, Bayer, Eli Lilly, GSK, Novartis, Pfizer, United Therapeutics
3 Updated classification of Pulmonary Hypertension (4 th PH World Symposium Dana Point, CA 2008) 1. Pulmonary Arterial Hypertension (PAH) 3. PH due to lung disease and/or hypoxemia 1.Pulmonary veno-occlusive disease and/or capillary Hemangiomatosis 4. Chronic thromboembolic pulmonary hypertension (CTEPH) 2. PH due to left-heart disease 5. PH with unclear or multi- factorial mechanisms Simonneau G, et al. J Am Coll Cardiol 2009
4 Endothelial dysfunction in PAH Humbert, Sitbon, Simonneau. N Engl J Med 2004
5 PAH therapy: What are the ressources today? le Lung transplantation iv epoprostenol More therapies available - PGI 2 analogues (3) - ERA (2) - PDE5 inhibitors (2) Improving clinical outcome 1 drug Less complex therapies (oral, inh) 1990 s Today
6 4 th WS,PAH Evidence-based Treatment Algorithm ( JACC2009 ) Oral anticoagulants (E/B) - IPAH Diuretics ( E/A ) Oxygen* ( E/A ) Digoxin ( E/C ) Supervised rehabilitation ( E/B ) VASOREACTIVE Supportive therapy and general measures Expert referral ( E/A ) Acute vasoreactivity test (A for IPAH) (E/C for ( APAH Avoid excessive physical exertion ( E/A ) Birth control ( E/A ) Psychological and social support ( E/C ) Infection prevention ( E/A ) WHO Class I-IV Nifedipine, amlodipine, diltiazem ( B ) Sustained response (WHO ( I-II YES NO Nifedipine, amlodipine, diltiazem ( B ) NON-VASOREACTIVE GUIDELINES FOR INITIAL THERAPY Strength of Recommendation WHO Class II WHO Class III WHO Class IV Ambrisentan Ambrisentan, Bosentan Epoprostenol IV Bosentan Iloprost inh, A Sildenafil Epoprostenol IV Sildenafil, B Tadalafil Treprostinil SC, Tadalafil Iloprost inhaled C Beraprost Treprostinil SC E/B Ambrisentan, Bosentan, Sildenafil E/C Sitaxsentan, Tadalafil NA Treprostinil inh+, Treprostinil inh+ Iloprost IV Iloprost IV, Treprostinil IV Treprostinil IV Initial combination therapy Sequential combination therapy INADEQUATE CLINICAL RESPONSE *To maintain O 2 at 92% +NDA in review PDE-5 I + ( B ) Prostanoids + ( B ) + ( B ) ERA INADEQUATE CLINICAL RESPONSE AS (E/B) and/or lung transplant ( E/A )
7 Evaluation of specific PAH therapies in different PAH subgroups Idiopathic Héritable Drugs and toxins Associated with other diseases: -Connective tissue diseases -HIV infection -Portal hypertension -Systemic to pulmonary shunts -Schistosomiasis -Chronic hemolytic anemias
8 Evaluation of specific PAH therapies in different PAH subgroups 85% of patients included in RCTs are idiopathic, heritable, drugs induced PAH or PAH associated with CTD No RCTs in PAH associated with HIV infection, portal hypertension or shistosiomasis Only one RCT in Eisenmenger syndrome and PAH associated with Sickle cell disease
9 Circulation,2006
10 A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease Florence Parent, Dora Bachir, Jocelyn Inamo, François Lionnet, Françoise Driss Gylna Loko, Anoosha Habibi, Soumiya Bennani, Laurent Savale, Serge Adnot, Bernard Maitre, Azzedine Yaïci, Leila Hajji, Dermot S. O Callaghan,Pierre Clerson, Robert Girot, Frederic Galacteros and Gerald Simonneau New Engl J Med 2011
11 Sickle Cell Disease patients screened n=403 Sickle Cell Disease patients included n=385 Doppler Echocardiograph screening Tricuspid Regurgitant Jet Velocity (TRJV) TRJV < 2.5 m/sec Group 1 No Pulmonary Hypertension n=289 (75%) TRJV 2.5 m/sec n=96 patients (25%) Pulmonary Hypertension suspected Right-heart catheterization Group 2 Pulmonary Hypertension excluded n=72 (19%) Group 3 Pulmonary Hypertension confirmed n=24 (6.2%)
12 Hemodynamics in different PH Subgroups No of Patients (Percentage) Pre-capillary PAH 11 (2.9%) Post-capillary PH 13 (3.3%) No PH on RHC 72 (18.7%) mpap (mm Hg) spap (mm Hg) dpap (mm Hg) RAP (mm Hg) PCWP (mm Hg) CO (L/min) PVR (dyn.s.cm -5 ) Parent et al;new Engl J Med 2011
13 14 Machado R Blood Prepublished online April 28, 2011 Machado R Effects of Sildenafil in PAH associated with Sikle cell disease The walk-phasst study was a double-bind, placebo controlled trial of 16 weeks to test safety and efficacy of sildenafil in PAH patients with SSD The NIH stopped the study,due to safety concerns when 33 patients had completed the trial sildenafil treated patients were likely to have more likely sickle cell pain crisis (35%) compared to placebo-treated patients (14%). Furthermore,there was no evidence of treatment-related improvement at time of study Machado R et al Blood 2011 (in press)
14 Rationale for combination therapy Malignant nature of PAH requires aggressive approach Successfully employed in chronic heart failure, HIV, cancer Combination therapy PAH pathogenesis = several pathways Sequential or up-front? Potential for synergistic effects and added benefit for the patient
15 Sequential combination therapy in PAH What is the evidence? Current therapy Added therapy Patients (n) Study duration Primary endpoint Primary EP met Secondary EP met Step Bosentan Iloprost 67 12STEP 1 weeks 6MWD No TTCW PACES 2 Epoprostenol Sildenafil weeks 6MWD Yes TTCW PHIRST 3 Naïve or bosentan Tadalafil 405 (206) 16 weeks 6MWD Yes / (No) TTCW, (No) TRIUMPH-1 4 Bosentan or sildenafil Treprostinil (inhaled) weeks 6MWD Yes No FREEDOM-C 5 Bosentan and/or sildenafil Treprostinil (oral) weeks 6MWD No No McLaughlin VV, Am J Respir Crit Care Med 2006 Simonneau G,. Ann Intern Med Galiè N Circulation McLaughlin V, J Am Coll Cardiol 2010;. identifier NCT
16 % change Effect of up-front combination therapy BREATHE-2: bosentan & epoprostenol 6-MWD (m) TPR change from baseline (%) Baseline (mean and 95% CI) Placebo + epo (n = 10) Bos + epo (n = 19) 0-20 Placebo + epo (n = 10) 0-20 Bos + epo (n = 19) Week 16 (median and 95% CI) Placebo + epo (n = 10) Bos + epo (n = 19) Baseline Wk Baseline Wk 16 6-MWD (m) Humbert M, et al. Eur Respir J 2004;
17 PVR (d.s.cm -5 ) Effect of up-front combination therapy Cumulative survival BREATHE-2: Epo + bosentan combination therapy (n = 23) p = Epoprostenol monotherapy (n = 46) -48 ± 17% -29 ± 17% Epo + bosentan combination therapy (n=23) P= Epoprostenol monotherapy (n=46) 0 Baseline 3-month Baseline 3-month Time (months) Kemp K, et al. J Heart Lung Transpl In press.
18 4 th WS,PAH Evidence-based Treatment Algorithm ( JACC2009 ) Oral anticoagulants (E/B) - IPAH Diuretics ( E/A ) Oxygen* ( E/A ) Digoxin ( E/C ) Supervised rehabilitation ( E/B ) VASOREACTIVE Supportive therapy and general measures Expert referral ( E/A ) Acute vasoreactivity test (A for IPAH) (E/C for ( APAH Avoid excessive physical exertion ( E/A ) Birth control ( E/A ) Psychological and social support ( E/C ) Infection prevention ( E/A ) WHO Class I-IV Nifedipine, amlodipine, diltiazem ( B ) Sustained response (WHO ( I-II YES NO Nifedipine, amlodipine, diltiazem ( B ) NON-VASOREACTIVE GUIDELINES FOR INITIAL THERAPY Strength of Recommendation WHO Class II WHO Class III WHO Class IV Ambrisentan Ambrisentan, Bosentan Epoprostenol IV Bosentan Iloprost inh, A Sildenafil Epoprostenol IV Sildenafil, B Tadalafil Treprostinil SC, Tadalafil Iloprost inhaled C Beraprost Treprostinil SC Iloprost IV Iloprost IV, Treprostinil IV E/B Treprostinil IV Ambrisentan, Bosentan, Sildenafil E/C Sitaxsentan, Tadalafil NA Treprostinil inh+, Treprostinil inh+ Sequential combination therapy Initial combination therapy INADEQUATE CLINICAL RESPONSE *To maintain O 2 at 92% +NDA in review PDE-5 I + ( B ) Prostanoids + ( B ) + ( B ) ERA INADEQUATE CLINICAL RESPONSE AS (E/B) and/or lung transplant ( E/A )
19 AMBITION STUDY A randomised, multicenter study of first-line AMBrisentan and Tadalafil combination therapy in subjects with pulmonary arterial hypertension To compare 2 treatment strategies upfront combo (amb+tad) vs mono (amb or tad) Event-driven trial Primary objective: time to clinical failure Secondary objectives: compare the changes in other clinical measures safety and tolerability 6MWT at peak and trough level
20 Classification of Pulmonary Hypertension (4 th PH World Symposium Dana Point, CA 2008) 1. Pulmonary Arterial Hypertension Prostanoids, ERA, PDE5i 7 drugs approved 2. Pulmonary hypertension due to left heart disease 3. Pulmonary hypertension due to lung diseases and / or hypoxia Oxygen therapy if needed In out of proportion PH: Which role for PAH therapy? 4. Chronic thromboembolic pulmonary hypertension Treatment of left heart failure In out of proportion PH: Which role for PAH therapy? Surgery when possible In non operable forms: Which role for PAH therapy? Simonneau G, et al. J Am Coll Cardiol 2009
21 . 2 Pulmonary hypertension due to left heart disease Systolic dysfunction Diatolic dysfunction Valvular diseases Represents probably the most frequent group 2 categories: -Passive post-capillary Pulmonary hypertension -Mixed pre and post-capillary pulmonary hypertension Which definition??
22 Post-capillary PH: Pathophysiology and definition Passive (Pure) Venous component Reactive -out of proportion (Mixed Pre & Post capillary) Arterial component Increased hydrostatic pressure Pulmonary vascular remodeling X X TPG 12 mmhg 1 dpap PCWP 8 mmhg² TPG > 12 mmhg 1 dpap PCWP > 8 mmhg² 1. Galiè N et al. Eur Respir J Chemla D et al. Eur Respir J 2002
23 72 year-old male,obese,systemic hypertension,diabetis and severe left diastolic dysfunction 4 March March 2010* RAP, mm Hg PAPs/d-m, mmhg 110/ /25 32 PCWP, mmhg TPG, mmhg 33 8 dpap PCWP 5 3 CI, L.min.m² 2,5 2,43 PVR, WU 5,9 1,4 * Second RH cath after one week of high doses of diuretics
24 3. PH withlungdiseases/hypoxemia Chronic obstructive pulmonary disease Interstitial lung disease Other pulmonary diseases with mixed obstructive and restrictive pattern Represents also an important goup (10% of CLD) PH is generally mild or moderate Some rare cases(1%) have severe PH (Mean PAP>35mmHg) These patients generaly show moderate lung function impairement (disproportionate PH) and could benefit from Specific PAH treatment The effects of specific PAH therapies in this setting need to be properly evaluated
25 Mechanisms of Pulmonary hypertension in CTEPH Obstruction of proximal pulmonary arteries by organized fibrotic clots, surgically accessible Small vessel pulmonary vascular disease: Distal fibrotic clots surgically inaccessible. Pulmonary vascular remodeling in non- obstructed vascular bed (similar to IPAH)
26 J Am Coll Cardiol 2008;52: Inclusion criteria: Symptomatic PH in WHO FC II to IV due to CTEPH - V/Q lung scan and pulmonary angiography Judged inoperable (distal lesions) OR Persistent or recurrent PH after PEA Operability assessed retrospectively
27 % of baseline PVR at week 16 (geometric means) BENEFIT STUDY co-primary endpoint: PVR 110% 100% 90% 80% Placebo n = 71 Bosentan n = 66 70% 60% Treatment effect: 24.1% (95% CI: 31.5, 16.0) p <0.0001; Wilcoxon Jaïs X, et al. J Am Coll Cardiol 2008; 52:
28 BENEFIT STUDY co-primary endpoint: 6-MWD 6-MWD Placebo (n = 73) Bosentan (n = 67) Baseline (mean SD, m) Week 16 (mean SD, m) Change from baseline (mean SD, m) Treatment effect* (m) 2.2 (95% CI: 22.5, 26.8); p = ; Wilcoxon test *Treatment effect is expressed as a mean difference with related CIs Jaïs X, et al. J Am Coll Cardiol 2008;
29 Effects of sildenafil in CTEPH patients a 12-week RCT for persistent PH post PEA or de novo distal CTEPH Change from baseline Difference between treatments Sildenafil (n = 9) Placebo (n = 10) Difference (95% CI) p value Change in WHO class Improved >1 class Deteriorated >1 class 44% 0% 0% 20% MWD (m) (-23.9 to 58.8) Borg dyspnoea index (-2.4 to 0.6) NT-proBNP (pg/ml) (-779 to -223) RA (mmhg) (-6.1 to 4.2) mpap (mmhg) (-12.4 to 0.1) CI (L/min/m 2 ) (-0.4 to 0.4) PVR (dyn/s/cm 5 ) (-389 to -6) Suntharalingham J, et al. Chest 2008
30 Conclusion The effects of Prostanoids, ERA and PDE5 inhibitors have been properly evaluated in idiopathic, heritable, drugs induced PAH and PAH associated with CTD Data in other PAH subgroups are scarce and more informations are needed The role of o specific PAH treaments beyond PAH remains not established and RCTs are needed especially in PH associated with left heart disease, with chronic lung disease as well as in non operable CTEPH
Progress in PAH. Gerald Simonneau
Progress in PAH Gerald Simonneau National Reference center for Pulmonary Hypertension Bicetre University Hospital, INSERM U 999 Paris-Sud University Le Kremlin Bicêtre France Clinical Classification of
More informationTherapeutic approaches in P(A)H and the new ESC Guidelines
Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationTHERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationReal-world experience with riociguat in CTEPH
Real-world experience with riociguat in CTEPH Matthias Held Center of Pulmonary Hypertension and Pulmonary Vascular Disease, Medical Mission Hospital, Würzburg, Germany Tuesday, 29 September ERS International
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationΠνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION. Αναστασία Ανθη
Πανελλήνια Σεμινάρια Ομάδων Εργασίας 2017 k Πνευμονική Υπέρταση: Μια ΚΡΙΤΙΚΗ ματιά στις κλινικές μελέτες - AMBITION Αναστασία Ανθη Β Κλιν. Εντατικής Θεραπείας & Διακλινικό Ιατρείο Πνευμ. Υπέρτασης Π.Γ.Ν.
More informationUpdate in Pulmonary Arterial Hypertension
Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with
More informationThe Case of Marco Nazzareno Galiè, M.D.
The Case of Marco Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationChronic Thromboembolic Pulmonary Hypertention CTEPH
Chronic Thromboembolic Pulmonary Hypertention CTEPH Medical Management Otto Schoch, Prof. Dr. Klinik für Pneumologie und Schlafmedizin Kantonsspital St.Gallen CTEPH: Medical Management Diagnostic aspects
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationThe Case of Lucia Nazzareno Galiè, M.D.
The Case of Lucia Nazzareno Galiè, M.D. DIMES Disclosures Consulting fees and research support from Actelion Pharmaceuticals Ltd, Bayer HealthCare, Eli Lilly and Co, GlaxoSmithKline and Pfizer Ltd Clinical
More informationAdvances in Pharmacotherapy of PAH
24 th Annual Advances in Heart Disease Advances in Pharmacotherapy of PAH Gabriel Gregoratos, MD 12/14/2007 UCSF Cardiology 1 Faculty Disclosure Statement for Gabriel Gregoratos, MD Nothing to disclose
More informationIV PGI2 vs. Inhaled PGI2 in chronic lung disease
Inhaled Therapies for PAH Erika Berman Rosenzweig, MD Associate Professor of Clinical Pediatrics (in Medicine) Director, Pulmonary Hypertension Center Columbia University Medical Center Disclosures Has
More informationRole of Combination PAH Therapies
Role of Combination PAH Therapies Ronald J. Oudiz, MD, FACP, FACC Associate Professor of Medicine, David Geffen School of Medicine at UCLA Director, Liu Center for Pulmonary Hypertension Los Angeles Biomedical
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More information22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment
22nd Annual Heart Failure 2018 an Update on Therapy Pulmonary Arterial Hypertension: Contemporary Approach to Treatment Ronald J. Oudiz, MD, FACP, FACC, FCCP Professor of Medicine The David Geffen School
More informationACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO
ACCP PAH Medical Therapy Guidelines: 2007 Update David Badesch, MD University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch has received grant/research support
More informationDisclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline
Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar
More informationWhere are we now in the longterm. of PAH and CTEPH? Hits and misses of medical treatment. Hap Farber Boston University School of Medicine, Boston, USA
Where are we now in the longterm management of PAH and CTEPH? Hits and misses of medical treatment Hap Farber Boston University School of Medicine, Boston, USA Monday, 28 September ERS International Congress
More informationPulmonary Arterial Hypertension: The Approach to Management in 2019
Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir S. Janmohamed M.D. FACC Medical Director Mechanical Circulatory Support/Heart Failure Program Mercy General Hospital/Mercy Medical
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationCombination therapy in the treatment of pulmonary arterial hypertension 2015 update
Journal of Rare Cardiovascular Diseases 2015; 2 (4): 103 107 www.jrcd.eu REVIEW ARTICLE Rare diseases of pulmonary circulation Combination therapy in the treatment of pulmonary arterial hypertension 2015
More informationApproach to Pulmonary Hypertension in the Hospital
Approach to Pulmonary Hypertension in the Hospital Todd M Bull MD Professor of Medicine Director Pulmonary Vascular Disease Center Director Center for Lungs and Breathing Division of Pulmonary Sciences
More information4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology
Pulmonary Hypertension: An Update Tim Williamson, MD, FCCP Director, Pulmonary Vascular Program University of Kansas Hospital Normal Physiology 1 Pulmonary Perfusion 101 High Pressure Low Pressure Pulmonary
More informationCardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON
Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac
More informationPulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of
More informationPulmonary hypertension in sarcoidosis
Pulmonary hypertension in sarcoidosis Olivier SITBON Centre de Référence de l Hypertension Pulmonaire Sévère Hôpital Universitaire de Bicêtre INSERM U999 Université Paris-Sud Le Kremlin-Bicêtre France
More informationTreatment of Paediatric Pulmonary Hypertension
Treatment of Paediatric Pulmonary Hypertension Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine 1 Disclosures I have the following financial relationships
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationUpdates in Pulmonary Hypertension Pharmacotherapy. Ziad Sadik PharmD BCPS
Updates in Pulmonary Hypertension Pharmacotherapy Ziad Sadik PharmD BCPS Disclosure Information I have no financial relationship to disclose AND I will not discuss off label use and/or investigational
More informationNavigating the identification, diagnosis and management of pulmonary hypertension using the updated ESC/ERS guidelines
Navigating the identification, diagnosis and management of pulmonary hypertension using the updated ESC/ERS guidelines Host: Marc Humbert Speaker: Simon Gibbs Marc HUMBERT, MD, PhD Professor of Respiratory
More informationPulmonary Hypertension: Clinical Features & Recent Advances
Pulmonary Hypertension: Clinical Features & Recent Advances Lisa J. Rose-Jones, MD Assistant Professor of Medicine, Division of Cardiology Advanced Heart Failure/Cardiac Transplantation & Pulmonary Hypertension
More informationPulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes
Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal
More informationPULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER
PULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER OUTLINE Brief review of WHO Group Classification Scheme Subgroups we ll focus on: WHO Group I Pulmonary Arterial
More informationOral Therapies for Pulmonary Arterial Hypertension
Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationCONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION
CONUNDRUMS IN PULMONARY ARTERIAL HYPERTENSION MOHAMMED RAFIQUE ESSOP MILPARK HOSPITAL and UNIVERSITY OF THE WITWATERSRAND POINTS FOR DISCUSSION What is the pathogenetic mechanism of PAH? Importance of
More informationMACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)
MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial
More informationSATELLITE SYMPOSIUM OF MSD. sgc Stimulation for the treatment of PH. Real life management of PAH: case presentation
SATELLITE SYMPOSIUM OF MSD sgc Stimulation for the treatment of PH Real life management of PAH: case presentation Eftychia Demerouti MD, MSc, PhD Cardiologist Onassis Cardiac Surgery Center Conflict of
More informationTeaching Round Claudio Sartori
Teaching Round 14.03.2017 Claudio Sartori Cas clinique Femme 47 ans, connue pour un BPCO, asthénie, douleurs thoraciques, dyspnée à l effort, œdèmes membres inférieurs, deux syncopes. Tabac, BMI 31 kg/m2
More informationPULMONARY HYPERTENSION For Cardiologists
PULMONARY HYPERTENSION For Cardiologists Pulmonary Hypertension Classification Pulmonary Hypertension General Definition Resting Systolic PAP Resting Diastolic PAP Resting Mean PAP > 35mmHg > 15mmHg >
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Draft remit / appraisal objective: Draft scope To appraise the clinical and cost effectiveness
More informationAcute Vasodilator Testing in Pulmonary Hypertension: What, When, and How?
Acute Vasodilator Testing in Pulmonary Hypertension: What, When, and How? Teresa De Marco, MD University of California, San Francisco Disclosures: Grants/Research: United Therapeutics, Lung Biotechnology,
More informationComparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry
nazzareno.galie@unibo.it Comparison between adult and pediatric populations with I/HPAH and PAH-CHD in the Bologna ARCA registry Nazzareno Galiè, MD, FESC, FRCP (Hon), DIMES 2 Comprehensive clinical classification
More informationA Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article A Hemodynamic Study of Pulmonary Hypertension in Sickle Cell Disease Florence Parent, M.D., Dora Bachir, M.D., Jocelyn Inamo, M.D.,
More informationTherapy Update: ERAs. Review of Mechanism. Disclosure Statements. Outline. Disclosure: Research support from United Therapeutics
1 Therapy Update: ERAs Disclosure Statements Disclosure: Research support from United Therapeutics Most of the medications discussed in this presentation are off-label usage Nidhy Varghese, MD Pulmonary
More informationOptimal management of severe pulmonary arterial hypertension
Eur Respir Rev 2011; 20: 122, 254 261 DOI: 10.1183/09059180.00007011 CopyrightßERS 2011 REVIEW Optimal management of severe pulmonary arterial hypertension O. Sitbon and G. Simonneau ABSTRACT: Over the
More informationΔΙΑΓΝΩΣΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΤΗΣ ΧΡΟΝΙΑΣ ΘΡΟΜΒΟΕΜΒΟΛΙΚΗΣ ΥΠΕΡΤΑΣΗΣ (CTEPH)
Aristotle University of Thessaloniki Cardiology Clinic, AHEPA Hospital ΔΙΑΓΝΩΣΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΤΗΣ ΧΡΟΝΙΑΣ ΘΡΟΜΒΟΕΜΒΟΛΙΚΗΣ ΥΠΕΡΤΑΣΗΣ (CTEPH) Charalampos I. Karvounis, MD Professor of Cardiology Aristotle
More informationPulmonary Hypertension in Chronic Obstructive Pulmonary Disease
Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Deedre Boekweg RN, BSN, CCRP Intermountain Medical Center Murray, UT Kerri Akaya Smith, MD University of Pennsylvania Philadelphia, PA PHPN
More informationPaediatric PAH in the current era
Paediatric PAH in the current era Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine Paediatric PAH in the current era & A Gap Analysis Dunbar Ivy, MD The
More informationNational Horizon Scanning Centre. Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class III. April 2008
Oral and inhaled treprostinil for pulmonary arterial hypertension: NYHA class April 2008 This technology summary is based on information available at the time of research and a limited literature search.
More informationPulmonary Arterial Hypertension (PAH): Emerging Therapeutic Strategies
Pulmonary Arterial Hypertension (PAH): Emerging Therapeutic Strategies Nick H. Kim, M.D. Clinical Professor of Medicine Director, Pulmonary Vascular Medicine Clinical Service Chief, PCCSM La Jolla Pulmonary,
More informationPrognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies
Prognostic value of echocardiographic parameters in patients with pulmonary arterial hypertension (PAH) treated with targeted therapies E. Beciani, M. Palazzini, C. Bachetti, F. Sgro, E. Conficoni, E.
More informationUpdate on pulmonary HTN
Update on pulmonary HTN Feras Bader, MD, MS, FACC Associate Professor of Medicine- Cardiology University of Utah School of Medicine Director, Advanced Heart Failure and Transplant Program Dabbous Cardiac
More information*Division of Pulmonary, Sleep, and Critical Care Medicine, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA
The Relationship between NO Pathway Biomarkers and Response to Riociguat in the RESPITE Study of Patients with PAH Not Reaching Treatment Goals with Phosphodiesterase 5 Inhibitors James R Klinger,* Raymond
More informationPulmonary Arterial Hypertension in Pa)ents with HIV Infec)on: New Thoughts, BeGer Outcomes
Pulmonary Arterial Hypertension in Pa)ents with HIV Infec)on: New Thoughts, BeGer Outcomes Hap Farber, MD Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures Consultant:
More informationΕιδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών
Ειδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών . Updated Clinical Classification of Pulmonary Hypertension
More informationTadalafil for the Treatment of Pulmonary Arterial Hypertension
Journal of the American College of Cardiology Vol. 60, No. 8, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.05.004
More informationIncreasing knowledge about the pathophysiology
Eur Respir Rev 27; 16: 12, 13 18 DOI: 1.1183/95918.124 CopyrightßERSJ Ltd 27 Dual endothelin receptor antagonism: setting standards in PAH M. Humbert ABSTRACT: Endothelin (ET) has emerged as a key mediator
More informationPulmonary Hypertension Due to Left Heart Disease
ACC Middle East Conference 2018 Pulmonary Hypertension Due to Left Heart Disease Ammar Chaudhary, MBChB, FRCPC Advanced Heart Failure & Transplantation King Faisal Specialist Hospital and Research Center
More informationPulmonary arterial hypertension (PAH) is
Eur Respir Rev 21; 19: 118, 314 32 DOI: 1.1183/95918.781 CopyrightßERS 21 REVIEW Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease
More informationADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationPulmonary Hypertension Perioperative Management
Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida Introduction Definition
More informationΠνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ
Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ PH is defined as PAPm 25 mm Hg at rest The general definition of PH remains unchanged Most of the relevant epidemiological and therapeutic studies have used the 25 mm
More information2015 State-of-the-Art Management of Pulmonary Hypertension Based on an Understanding of the Various Etiologies
2015 State-of-the-Art Management of Pulmonary Hypertension Based on an Understanding of the Various Etiologies Vallerie V. McLaughlin, MD, FACC, FAHA Kim A Eagle MD Endowed Professor of Cardiovascular
More informationSTARTS-1 and -2. Barst R, Ivy DD, et al. Circulation 2012;125:
STARTS-1 and -2 A randomized, double-blind,16 week placebo controlled, dose ranging, parallel group study of oral monotherapy sildenafil in treatment naive children, aged 1-17 years, with pulmonary arterial
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More information2009 ESC ERS Pulmonary Hypertension Guidelines and Connective Tissue Disease Norifumi Nakanishi 1
Allergology International. 2011;60:419-424 DOI: 10.2332 allergolint.11-rai-0362 REVIEW ARTICLE 2009 ESC ERS Pulmonary Hypertension Guidelines and Connective Tissue Disease Norifumi Nakanishi 1 ABSTRACT
More informationReal life management of CTEPH: patient case
2 nd International Congress on cardiovascular imaging in clinical practice k Real life management of CTEPH: patient case Anastasia Anthi Pulmonary Hypertension Clinic, Attikon University Hospital, Athens
More informationCase Presentation : Pulmonary Hypertension: Diagnosis and Imaging
Case Presentation 9.40-11.20: Pulmonary Hypertension: Diagnosis and Imaging Eftychia Demerouti MD, MSc, PhD Cardiologist Onassis Cardiac Surgery Center Conflicts of interest Consulting fees and fees for
More informationObjectives. Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease
Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease Erika Berman Rosenzweig, MD Director, Pulmonary Hypertension Center Associate Professor of Clinical Pediatrics (in Medicine)
More informationPVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program
PVDOMICS Study Introduction Kristin Highland, MD Gerald Beck, PhD NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of
More informationPulmonary Hypertension: Definition and Unmet Needs
Heart Failure Center Hadassah University Hospital Pulmonary Hypertension: Definition and Unmet Needs Israel Gotsman The Heart Failure Center Hadassah University Hospital I DO NOT have a financial interest/
More information9/15/11. Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September Scleroderma. Hard skin
Dr. Vivien Hsu Director, UMDNJ Scleroderma Program New Brunswick, NJ September 2011 Scleroderma Hard skin 1 No diagnostic test for scleroderma Pathogenesis is unknown prominent features of disease reflect
More informationLa terapia dell ipertensione arteriosa polmonare oggi
La terapia dell ipertensione arteriosa polmonare oggi PneumoTrieste 2017 Trieste 3 5 Aprile 2017 Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale
More informationPVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program
PVDOMICS Study Introduction Kristin Highland, MD Gerald Beck, PhD NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of
More informationPULMONARY HYPERTENSION
PULMONARY HYPERTENSION REVIEW & UPDATE Olga M. Fortenko, M.D. Pulmonary & Critical Care Medicine Pulmonary Vascular Diseases Sequoia Hospital 650-216-9000 Olga.Fortenko@dignityhealth.org Disclosures None
More informationACTIVITY DESCRIPTION Target Audience Learning Objectives
ACTIVITY DESCRIPTION Target Audience This continuing medical education activity is planned to meet the needs of primary care physicians who can contribute to early detection of disease and who are responsible
More informationThe US REVEAL Registry
Pulmonary Hypertension: Lessons from Contemporary Registries The US REVEAL Registry ESC August 30, 2010 Dave Badesch, MD University of Colorado Disclosures Dr. Badesch has received grant/research support
More informationAdvanced Therapies for Pharmocological Treatment of Pulmonary Arterial Hypertension. Original Policy Date
MP 5.01.07 Advanced Therapies for Pharmocological Treatment of Pulmonary Arterial Hypertension Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationIn focus The paediatric PAH population Clinicians Perspectives
In focus The paediatric PAH population Clinicians Perspectives Maurice Beghetti Pediatric Cardiology University Children s Hospital HUG and CHUV Pulmonary Hypertension Program HUG Centre Universitaire
More informationClinical implication of exercise pulmonary hypertension: when should we measure it?
Clinical implication of exercise pulmonary hypertension: when should we measure it? Jang-Young, Kim Wonju College of Medicine, Yonsei Univ. Exercise pulmonary hypertension (EPH) Introduction of pulmonary
More informationIdentifying Appropriate Treatment & Management Strategies in Pulmonary Arterial Hypertension
Identifying Appropriate Treatment & Management Strategies in Pulmonary Arterial Hypertension Harold I. Palevsky, M.D. Perelman School of Medicine of the University of Pennsylvania Penn Presbyterian Medical
More informationWhat Surgeons Need to Know About. Pulmonary Arterial Hypertension
What Surgeons Need to Know About Pulmonary Arterial Hypertension David B. Badesch, MD Professor of Medicine University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch
More informationTherapeutic Categories Outlook
Equity Research Health Care Therapeutic Categories Outlook Comprehensive Study February 2017 Alzheimer s Disease Bone Diseases Cardiovascular Central Nervous System Dermatology Diabetes/Obesity Epilepsy
More informationFiltering through the Facts: Portopulmonary Hypertension Saturday, September 19, :15 10:05 a.m.
Filtering through the Facts: Portopulmonary Hypertension Saturday, September 19, 2015 9:15 10:05 a.m. Joel Wirth, MD Pulmonary & Critical Care Medicine Maine Medical Center, Portland, ME Disclosures Dr.
More informationDespite updated guidelines and advances. Early detection and management of pulmonary arterial hypertension REVIEW
Eur Respir Rev 212; 21: 126, 36 312 DOI: 1.1183/95918.5112 CopyrightßERS 212 REVIEW Early detection and management of pulmonary arterial hypertension Marc Humbert*, J. Gerry Coghlan # and Dinesh Khanna
More informationΦαρµακοθεραπεία στη Πνευµονική Αρτηριακή Υπέρταση: Αρχική ή διαδοχική συνδυαστική θεραπεία
37 ο Πανελλήνιο Καρδιολογικό Συνέδριο Αθήνα, Οκτώβριος 2016 k Φαρµακοθεραπεία στη Πνευµονική Αρτηριακή Υπέρταση: Αρχική ή διαδοχική συνδυαστική θεραπεία Αναστασία Ανθη Β Κλιν. Εντατικής Θεραπείας & Διακλινικό
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
More informationPulmonary Hypertension A-Z
Pulmonary Hypertension A-Z Lana Melendres-Groves UNM Pulmonary Hypertension Program Director Assistant Professor of Medicine Pulmonary/Critical Care Division 9/17/16 Disclosures Advisory board member Actelion
More informationModern Management of Pulmonary Hypertension: Expert Guidance for Individualized Care in the Community Practice Setting
Modern Management of Pulmonary Hypertension: Expert Guidance for Individualized Care in the Community Practice Setting Agenda 1. Welcome & introduction 2. Brief summary of best practices for optimal screening,
More informationCurrent and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06
Current and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06 Pulmonary Hypertension A mean pressure of greater than 25 mm Hg at rest (normal ~14 mm Hg) or greater
More informationRight Heart Catheterization. Franz R. Eberli MD Chief of Cardiology Stadtspital Triemli, Zurich
Right Heart Catheterization Franz R. Eberli MD Chief of Cardiology Stadtspital Triemli, Zurich Right Heart Catheterization Pressure measurements Oxygen saturation measurements Cardiac output, Vascular
More informationELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY
ELIGIBILITY CRITERIA FOR PULMONARY ARTERIAL HYPERTENSION THERAPY Contents Eligibility criteria for Pulmonary Arterial Hypertension therapy...2-6 Initial Application for funding of Pulmonary Arterial Hypertension
More informationManagement of Pulmonary Arterial Hypertension: Evolution in Management
Management of Pulmonary Arterial Hypertension: Evolution in Management Stephen C. Mathai, MD MHS The Johns Hopkins Pulmonary Hypertension Program Assistant Professor of Medicine Johns Hopkins University
More information